hVIVO shares rise 23% as CEO and CFO buy in after contract setbacks

hVIVO shares surged 23% after CEO Mo Khan and CFO Stephen Pinkerton purchased a combined 1.8 million shares at 8.9p, a move interpreted by Peel Hunt as a sign of confidence following recent contract cancellations and study delays in the US. The purchases aim to reassure investors amidst near-term pressures, including a reduced contracted order book for 2025, even as the company cites a record sales pipeline and diversification efforts.

Analysis

Shares in hVIVO PLC (AIM:HVO) experienced a significant 23% surge to 10.76p on Monday, following the disclosure that its Chief Executive, Mo Khan, and Chief Financial Officer, Stephen Pinkerton, collectively acquired 1.8 million shares at 8.9p each. This insider buying, with Khan purchasing 1.1 million shares and Pinkerton 683,000, is interpreted by Peel Hunt as a strategic move to bolster investor confidence. The share purchases occurred shortly after hVIVO announced the termination of a major human challenge trial contract and a study delay, both attributed to prevailing uncertainty within the US clinical research market. While Peel Hunt acknowledges the near-term pressures, including a diminished contracted order book for 2025, the broker also highlights that management's actions signal conviction in the company's long-term strategy. This outlook is further supported by hVIVO's largest-ever sales pipeline and ongoing efforts to diversify its service offerings, notably into lab and storage services, which could mitigate the impact of recent contract setbacks.

Key Decisions for Investors

• Investors should view the substantial insider buying by hVIVO's CEO and CFO as a strong vote of confidence in the company's intrinsic value and future prospects, particularly following recent adverse contract news.
• Carefully weigh the positive signal from management's share purchases against the acknowledged near-term headwinds, specifically the reduced 2025 contracted order book and the ongoing uncertainties in the US clinical research market.
• Monitor hVIVO's progress in converting its record sales pipeline and advancing its diversification into lab and storage services, as these factors will be critical in validating the executives' optimistic stance and offsetting the impact of recent contract losses.